CYP4A22

Across TCGA pan-cancer cohorts, CYP4A22 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CYP4A22 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CYP4A22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYP4A22 expression acts as an unfavorable survival marker.

LIHC, PRAD, and LGG are the cancer types where CYP4A22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.118	0.716	.003	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LGG	DFS	Median	All	0.249	0.728	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CYP4A22–LIHC (OS)

Open the LIHC breakdown →